RenovoRx (RNXT) Return on Capital Employed (2021 - 2026)
RenovoRx (RNXT) posted Return on Capital Employed of 141.27% for Q1 2026, up 13.18% sequentially from 162.71% in Q4 2025, and down 2894.0% YoY from 5.06% in Q1 2025.
RenovoRx (RNXT) Return on Capital Employed (2021 - 2026) Analysis & Trends
RenovoRx has reported Return on Capital Employed for 6 years, with the latest figure at 141.27% in Q1 2026.
- Quarterly Return on Capital Employed fell 2894.0% year-over-year to 141.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 141.27% (down 2894.0% YoY) and the FY2025 annual result came in at 203.6%, up 17691.0% from the prior year.
- Return on Capital Employed improved to 141.27% in Q1 2026 per RNXT's latest filing, from 162.71% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 84.75% in Q2 2025 and troughed at 864.97% in Q4 2023.
- A 5-year average of 245.68% and a median of 144.95% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 72592 bps in 2023, then surged 71188 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 139.05% in 2022, then plunged by 522 bps to 864.97% in 2023, then surged by 82 bps to 153.09% in 2024, then declined by 6 bps to 162.71% in 2025, then grew by 13 bps to 141.27% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 141.27%, 162.71%, and 110.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | -124.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -124.98% |
| Mar 31, 2026 | -141.27% |
| Dec 31, 2025 | -162.71% |
| Sep 30, 2025 | -110.24% |
| Jun 30, 2025 | -84.75% |
| Mar 31, 2025 | -112.33% |
| Dec 31, 2024 | -153.09% |
| Sep 30, 2024 | -109.40% |
| Jun 30, 2024 | -144.95% |
| Mar 31, 2024 | -521.68% |
| Dec 31, 2023 | -864.97% |
| Sep 30, 2023 | -356.00% |
| Jun 30, 2023 | -293.35% |
| Dec 31, 2022 | -139.05% |
| Dec 31, 2021 | -34.80% |